What Happened?
Boston, MA-based Atea Pharmaceuticals Appointed Marc Van Hulle as Exec. Director, Financial Planning and Analysis / RandD Finance
About the Company
Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company`s deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV).
About the Person
Marc Van Hulle is Exec. Director, Financial Planning and Analysis / RandD Finance at Atea Pharmaceuticals. Previously, Marc held various senior HR leadership roles in the industry.
Info Source
News
Short Profile